TGFB1 and hepatocellular carcinoma: In the last years the interest has been focused on the TβRI kinase inhibitor Galunisertib, developed by Lilly (LY2157299, a selective ATP-mimetic inhibitor of TβRI) that has proved more efficient than neutralizing humanized antibodies, such as D10 against TβRII, in blocking the canonical TGF-β signaling in HCC cells, experiments that supported the use of this drug in preclinical and clinical trials (9, 222).